Heron Therapeutics Statistics
Share Statistics
Heron Therapeutics has 152.56M
shares outstanding. The number of shares has increased by 1.11%
in one year.
| Shares Outstanding | 152.56M |
| Shares Change (YoY) | 1.11% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | 75.21% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 43,438 |
| FTD / Avg. Volume | 2.16% |
Short Selling Information
The latest short interest is 33.3M, so 21.83% of the outstanding
shares have been sold short.
| Short Interest | 33.3M |
| Short % of Shares Out | 21.83% |
| Short % of Float | 28.38% |
| Short Ratio (days to cover) | 33.1 |
Valuation Ratios
The PE ratio is -17.18 and the forward
PE ratio is 23.38.
Heron Therapeutics's PEG ratio is
0.19.
| PE Ratio | -17.18 |
| Forward PE | 23.38 |
| PS Ratio | 1.62 |
| Forward PS | 1.1 |
| PB Ratio | -6.93 |
| P/FCF Ratio | -9.62 |
| PEG Ratio | 0.19 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Heron Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29,
with a Debt / Equity ratio of -5.28.
| Current Ratio | 2.29 |
| Quick Ratio | 1.7 |
| Debt / Equity | -5.28 |
| Debt / EBITDA | -35.16 |
| Debt / FCF | -7.33 |
| Interest Coverage | -1.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,182,663.93 |
| Profits Per Employee | $-111,311.48 |
| Employee Count | 122 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.73 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -46.4% in the
last 52 weeks. The beta is 1.33, so Heron Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -46.4% |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 42.14 |
| Average Volume (20 Days) | 2,008,587 |
Income Statement
In the last 12 months, Heron Therapeutics had revenue of 144.28M
and earned -13.58M
in profits. Earnings per share was -0.09.
| Revenue | 144.28M |
| Gross Profit | 105.64M |
| Operating Income | -11.53M |
| Net Income | -13.58M |
| EBITDA | -5.06M |
| EBIT | -7.55M |
| Earnings Per Share (EPS) | -0.09 |
Full Income StatementBalance Sheet
The company has 25.8M in cash and 177.76M in
debt, giving a net cash position of -151.96M.
| Cash & Cash Equivalents | 25.8M |
| Total Debt | 177.76M |
| Net Cash | -151.96M |
| Retained Earnings | -1.92B |
| Total Assets | 235.75M |
| Working Capital | 124.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -22.53M
and capital expenditures -1.71M, giving a free cash flow of -24.23M.
| Operating Cash Flow | -22.53M |
| Capital Expenditures | -1.71M |
| Free Cash Flow | -24.23M |
| FCF Per Share | -0.16 |
Full Cash Flow StatementMargins
Gross margin is 73.21%, with operating and profit margins of -7.99% and -9.41%.
| Gross Margin | 73.21% |
| Operating Margin | -7.99% |
| Pretax Margin | -9.41% |
| Profit Margin | -9.41% |
| EBITDA Margin | -3.5% |
| EBIT Margin | -7.99% |
| FCF Margin | -16.8% |
